Read by QxMD icon Read

hyperplasia of prostate

Mariateresa Di Stazio, Chiara Collesi, Diego Vozzi, Wei Liu, Mike Myers, Anna Morgan, Pio Adamo D Adamo, Giorgia Girotto, Elisa Rubinato, Mauro Giacca, Paolo Gasparini
Hereditary hearing loss (HHL) is an extremely heterogeneous disorder with autosomal dominant, recessive, and X-linked forms. Here, we described an Italian pedigree affected by HHL but also prostate hyperplasia and increased ratio of the free/total PSA levels, with the unusual and extremely rare Y-linked pattern of inheritance. Using exome sequencing we found a missense variant (r.206A>T leading to p.Asp69Val) in the TBL1Y gene. TBL1Y is homologous of TBL1X, whose partial deletion has described to be involved in X-linked hearing loss...
October 19, 2018: European Journal of Human Genetics: EJHG
H-W Qu, Y Jin, Z-L Cui, X-B Jin
OBJECTIVE: This study aims to investigate whether microRNA-373-3p could inhibit the progression of prostate cancer (PCa) by targeting and degrading AKT1. PATIENTS AND METHODS: Expression levels of microRNA-373-3p and AKT1 in PCa tissues and benign prostate hyperplasia (BPN) tissues were detected by quantitative Real-Time-Polymerase Chain Reaction (qRT-PCR). According to the follow-up data, survival curves and receiver operating characteristic (ROC) curves were drawn to investigate whether microRNA-373-3p could be served as a biomarker for early diagnosis and prognosis of PCa...
October 2018: European Review for Medical and Pharmacological Sciences
Shujing Li, Jianping Zhou, Yu Wang, Keqin Zhang, Junjie Yang, Xinling Zhang, Chunmei Wang, Hongbo Ma, Ji Zhou, Ellen He, Sven Skog
The aim of the present was to assess whether serum thymidine kinase 1 (STK1) concentration is a useful biomarker for the screening of benign prostatic hyperplasia (BPH) or prostate malignancy. Serum samples were collected from 123 patients with prostate carcinoma prior to surgery, biopsy or androgen deprivation therapy and at 3, 6 and 10 months following the procedure. A total of 205 patients with BPH and 266 healthy controls were also utilized. STK1 concentration and total prostate-specific antigen (PSA) were measured in patient serum by use of commercial assays...
November 2018: Oncology Letters
Kevin C Zorn, S Larry Goldenberg, Ryan Paterson, Alan So, Dean Elterman, Naeem Bhojani
INTRODUCTION: Surgical management options for lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) associated with prostates of small to moderate volume (<80 cc) are numerous, however, for men with enlarged prostates (>80 cc), many of these options are neither safe nor effective. Recently, Aquablation (PROCEPT BioRobotics, Inc., U.S.), a precise ultrasound-guided, robotically executed prostatic ablative procedure, has become available with U.S. Food and Drug Administration approval...
October 15, 2018: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
A Alcántara Montero, M Estacio García, M L Martínez-Berganza Asensio
No abstract text is available yet for this article.
October 13, 2018: Semergen
William Y Raynor, Abdullah Al-Zaghal, Thomas J Werner, Poul F Høilund-Carlsen, Abass Alavi
Primary prostatic calculi commonly present asymptomatically in men over the age of 50 years. Individual calculi form when the secretory tube is blocked by inflammation, prostatic secretions, or corpora amylacea. Although small prostatic calculi have been described as a component of normal aging, increased prevalence of calculi has been associated with benign prostatic hyperplasia and prostatitis. We are presenting prostatic calcification in a 69-year-old man as incidentally detected on F-NaF PET/CT. Although previous publications have reported F-NaF uptake portraying calcification in soft tissue, these findings demonstrate a new domain in which to assess calcium metabolism using F-NaF PET/CT...
October 15, 2018: Clinical Nuclear Medicine
Hyun Hwangbo, Da He Kwon, Eun Ok Choi, Min Yeong Kim, Kyu Im Ahn, Seon Yeong Ji, Jong Sik Kim, Kyung-Il Kim, No-Jin Park, Bum Hoi Kim, Gi-Young Kim, Su-Hyun Hong, Cheol Park, Ji-Suk Jeong, Yung Hyun Choi
BACKGROUND/OBJECTIVES: Benign prostatic hypertrophy (BPH) is a major cause of abnormal overgrowth of the prostate mainly in the elderly. Corni Fructus has been reported to be effective in the prevention and treatment of various diseases because of its strong antioxidant effect, but its efficacy against BPH is not yet known. This study was designed to evaluate the therapeutic efficacy of Corni Fructus water extract (CF) in testosterone-induced BPH rats. MATERIALS/METHODS: To induce BPH, rats were intraperitoneal injected with testosterone propionate (TP)...
October 2018: Nutrition Research and Practice
Bo-Ram Jin, Hyo-Jung Kim, Sang-Kyun Park, Myoung-Seok Kim, Kwang-Ho Lee, Il-Joo Yoon, Hyo-Jin An
Benign prostatic hyperplasia (BPH), an age-dependent disorder with a prevalence percentage of 60% in the 60s, has been found to involve an androgenic hormone imbalance that causes confusion between cell apoptosis and proliferation. Because general medications for BPH treatment have undesirable side effects, the development of effective alternative medicines has been considered. HBX-5 is a newly developed formula with the aim of improving BPH, and is composed of nine medicinal herbs. BPH was induced in the rats by intramuscular injection of testosterone propionate after castration...
October 14, 2018: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
Xian-Tao Zeng, Hong Weng, Jing Xiong, Qiao Huang, Lin-Lu Ma, Ying-Hui Jin, Xing-Huan Wang
Objective: To discover the correlation of clinical and physiological measures for benign prostatic hyperplasia in hypertensive and normotensive patients. Methods: From September 2016 to October 2017, 435 patients were enrolled for further selection. The parameters evaluated for eligible patients included prostate volume, systolic blood pressure, diastolic blood pressure, international prostate symptom score, etc. Then the eligible patients were divided into two groups according to hypertension condition, and the clinical and physiological parameters were compared between two groups...
2018: Frontiers in Physiology
Mojtaba Saffari, Seyyed Mohammad Hossein Ghaderian, Mir Davood Omrani, Mandana Afsharpad, Kimia Shankaie, Niusha Samadaian
PURPOSE: Prostate cancer is one of the most frequent incidences of cancer in men. Early detection is a very important step for selective and efficient therapy. The study of the functions and molecular mechanisms of miRNAs have increased our knowledge of the biological processes of cancer. There is a deregulation of several miRNAs that causes suppression of tumors or oncogenes in prostate cancer. Therefore, finding a novel miRNA that is involved in prostate cancer is urgently needed. This study aims to investigate the expression level of mir-let7b-3p and mir-548, which are involved in PTEN expression in tissue samples of prostate cancer patients versus benign prostate hyperplasia (BPH) and normal adjacent tissue...
October 8, 2018: Urology Journal
Raymond C Rosen, Claus G Roehrborn, Michael J Manyak, Juan Manuel Palacios-Moreno, Timothy H Wilson, Zrinka Lulic, Francois Giuliano
AIMS: Five-α reductase inhibitor (5ARI) therapy has been associated with sexual dysfunction in some patients. This study assessed the impact of a fixed-dose combination of the 5ARI dutasteride 0.5 mg and the α1 -adrenoceptor antagonist tamsulosin 0.4 mg (DUT-TAM FDC) on Men's Sexual Health Questionnaire (MSHQ) domain scores in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH). METHODS: This was a post hoc analysis of a double-blind, randomized, placebo-controlled, parallel-group, multicenter study in sexually active patients, aged ≥50 years, with a confirmed clinical diagnosis of BPH...
October 13, 2018: International Journal of Clinical Practice
Robert Q Thompson, Daniel Katz, Brendan Sheehan
The bark of Prunus africana may contain atranorin, atraric acid, beta-sitosterol and its esters, ferulic acid and its esters, and N-butylbenzene sulfonamide, compounds that have been shown to improve the conditions of benign prostatic hyperplasia, enlarged prostate. An analytical scheme, involving liquid-solid extractions, saponifications, and LC-APCI-MS (triple quadrupole) analysis, was developed, optimized, and validated to determine the compounds at μg/g levels. Limits of quantification were in the low ng/mL range except for beta-sitosterol...
October 5, 2018: Journal of Pharmaceutical and Biomedical Analysis
Dmitry Enikeev, Petr Glybochko, Leonid Rapoport, Zhamshid Okhunov, Mitchel O'Leary, Natalya Potoldykova, Roman Sukhanov, Mikhail Enikeev, Ekaterina Laukhtina, Mark Taratkin
BACKGROUND: The impact of number of endoscopic enucleation of the prostate techniques (holmium laser enucleation - HoLEP for example) on erectile function have already been investigated. However, the thulium-fiber laser, in this setting remains unstudied. In this study, we compared sexual function outcomes in patients with benign prostatic hyperplasia (BPH) treated with transurethral resection of the prostate (TURP) or thulium-fiber laser enucleation (ThuFLEP). METHODS: We performed a retrospective analysis of patients who underwent transurethral resection and endoscopic enucleation of the prostate for BPH; inclusion criteria was the presence of infravesical obstruction (IPSS > 20, Qmax < 10 mL/s)...
October 12, 2018: BMC Urology
Je-Won Ko, So-Won Park, Na-Rae Shin, Woong-Il Kim, Jong-Choon Kim, In-Sik Shin, Dong-Ho Shin
Benign prostate hyperplasia (BPH) is a male reproductive disease that has gained increasing importance in recent years. The present study investigated whether Pycnogenol® (PYC), a standardized French maritime pine bark extract, could prevent BPH induced by testosterone propionate (TP) in rats. Male Sprague-Dawley rats were randomly divided into five groups of six rats. One group was used as a normal control rats and the other groups received subcutaneous injections of TP for 4 weeks to induce BPH. In the two treatment groups, PYC (20 or 40 mg/kg) was administered daily for 4 weeks by oral gavage concurrently with the induction of TP...
September 2018: Laboratory Animal Research
Shu-Shang Chen, Mei-Jiao Lin, Ming-Fang Weng, Ling-Feng Zhu, Zhen Deng, Cheng-Yao Wu, Jin-Quan Cai, Wei-Zhen Wu, Jian-Ming Tan
To explore the influence of prostate size on the outcome of Plasmakinetic enucleation of the prostate (PkEP) for the treatment of benign prostate hyperplasia (BPH), The data of 892 patients with symptomatic BPH who underwent PkEP were retrospectively reviewed. Among them, 199 (22.31%) had the prostate size smaller than 40 g (Group 1), 409 (45.85%) between 40 and 79 g (Group 2), 197 (22.09%) between 80 and 120 g (Group 3), and 87 (9.75%) larger than 120 g (Group 4). Perioperative variables, perioperative and postoperative complications were recorded...
October 2018: Kaohsiung Journal of Medical Sciences
Eu Chang Hwang, Shreyas Gandhi, Jae Hung Jung, Mari Imamura, Myung Ha Kim, Ran Pang, Philipp Dahm
BACKGROUND: Benign prostatic hyperplasia (BPH) is a common condition in ageing men that may cause lower urinary tract symptoms (LUTS). Treatment aims are to relieve symptoms and prevent disease-related complications. Naftopidil is an alpha-blocker (AB) that has a high affinity for the A1d receptor that may have advantages in treating LUTS in this setting. This is an update of a Cochrane Review first published in 2009. Since that time, several large randomised controlled trials (RCTs) have been reported, making this update relevant...
October 11, 2018: Cochrane Database of Systematic Reviews
Hyun Soo Ahn, Se Joong Kim, Jong Bo Choi, Seol Ho Choo, Kang Hee Shim, Sun Il Kim
OBJECTIVES: To analyze actual long-term medical treatment of benign prostatic hyperplasia (BPH) and compare the incurred cost with that of BPH patient who underwent immediate surgery. PATIENTS AND METHODS: Patients who were first diagnosed with BPH from January 1, 2008 to December 31, 2010 were identified using the Clinical Data Warehouse. Hospital billing data generated by the electronic hospital management system were collected till December 2015. For the outpatient care, only procedures, materials and drugs directly related to the management of BPH were selected for the analysis...
October 10, 2018: BJU International
Hossam Elkhalil, Aiman Alshare, Gal Shafirstein, John Bischof
OBJECTIVE: Laser with 532-nm wavelength (GreenLightTM ) is clinically approved to treat benign prostatic hyperplasia (BPH). However, low rate of tissue ablation and excessive thermal coagulation are shortcomings of this therapy. The goal of this study was to use a mathematical model to identify clinically viable laser settings that have the potential to improve treatment time and outcomes. METHODS: A three-dimensional transient computational model was developed, validated against analytical and experimental results, and utilized to investigate the response of tissues subjected to continuous-wave and pulsed lasers emitting 532-nm light (GreenLightTM laser)...
October 10, 2018: International Journal of Hyperthermia
R Suarez-Ibarrola, J Salem, J Struck, A Miernik
No abstract text is available yet for this article.
October 9, 2018: Der Urologe. Ausg. A
Enis Rauf Coskuner, Burak Ozkan, Mehmet Gokhan Culha
INTRODUCTION: 5-Alpha reductase inhibitors (5-ARIs) are widely used in the treatment of benign prostatic hyperplasia (BPH) and androgenic alopecia (AGA). AIM: To examine all available data on the effects of 5-ARIs on sexual functioning in AGA treatment and to assess whether 5-ARIs increase the risk of sexual dysfunction. METHODS: A literature review of publications at PubMed related to the subject was used. MAIN OUTCOME MEASURE: We assessed erectile dysfunction, ejaculation impairment, and decreased libido...
October 6, 2018: Sexual Medicine Reviews
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"